Molecular Interaction Atlas (MIA) |
|
Indication(s) of Fomepizole |
Disease Entry |
ICD 11 |
Status |
REF |
Athylene glycol or methanol poisoning |
NE61
|
Approved |
[2] |
|
|
Fomepizole Interacts with 1 DTT Molecule(s)
DTT Name |
DTT ID |
UniProt ID |
Mode of Action |
REF |
Alcohol dehydrogenase 1A (ADH1A)
|
TT5AHZ0
|
ADH1A_HUMAN
|
Modulator
|
[4] |
------------------------------------------------------------------------------------ |
|
|
|
|
|
Fomepizole Interacts with 1 DME Molecule(s)
DME Name |
DME ID |
UniProt ID |
Mode of Action |
REF |
Cytochrome P450 2E1 (CYP2E1)
|
DEVDYN7
|
CP2E1_HUMAN
|
Metabolism
|
[5] |
------------------------------------------------------------------------------------ |
|
|
|
|
|
Fomepizole Interacts with 1 DOT Molecule(s)
DOT Name |
DOT ID |
UniProt ID |
Mode of Action |
REF |
Cytochrome P450 2E1 (CYP2E1)
|
OTHQ17JG
|
CP2E1_HUMAN
|
Decreases Activity
|
[6] |
------------------------------------------------------------------------------------ |
|
|
|
|
|
Indication(s) of Auranofin |
Disease Entry |
ICD 11 |
Status |
REF |
Inflammatory arthritis |
FA2Z
|
Approved |
[3] |
|
|
Auranofin Interacts with 1 DTT Molecule(s)
DTT Name |
DTT ID |
UniProt ID |
Mode of Action |
REF |
Steroid hormone receptor ERR (ESRR)
|
TTP3UTW
|
ERR1_HUMAN; ERR2_HUMAN; ERR3_HUMAN
|
Modulator
|
[4] |
------------------------------------------------------------------------------------ |
|
|
|
|
|
Auranofin Interacts with 2 DTP Molecule(s)
DTP Name |
DTP ID |
UniProt ID |
Mode of Action |
REF |
Multidrug and toxin extrusion protein 1 (SLC47A1)
|
DTZGT0P
|
S47A1_HUMAN
|
Substrate
|
[7] |
Organic cation transporter 1 (SLC22A1)
|
DTT79CX
|
S22A1_HUMAN
|
Substrate
|
[7] |
------------------------------------------------------------------------------------ |
|
|
|
|
|
Auranofin Interacts with 1 DOT Molecule(s)
DOT Name |
DOT ID |
UniProt ID |
Mode of Action |
REF |
Metallothionein-1A (MT1A)
|
OTKBH52X
|
MT1A_HUMAN
|
Increases ADR
|
[8] |
------------------------------------------------------------------------------------ |
|
|
|
|
|
|
|
|
|
|
|
|